Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [^99mTc]Tc-labeled counterparts be used to estimate dosimetry?

ABSTRACT:

Background

Gastrin releasing peptide receptor (GRPR)-directed radiopharmaceuticals for targeted radionuclide therapy may be a very promising addition in prostate and breast cancer patient management. Aiming to provide a GRPR-targeting theranostic pair, we have utilized the Tc-99m/Re-188 radiometal pair, in combination with two bombesin based antagonists, maSSS-PEG2-RM26 and maSES-PEG2-RM26. The two main aims of the current study were (i) to elucidate the influence of the radiometal-exchange on the biodistribution profile of the two peptides and (ii) to evaluate the feasibility of using the [^99mTc]Tc labeled counterparts for the dosimetry estimation for the [¹⁸⁸Re]Re-labeled conjugates.

Results

Both peptides were successfully labeled with Re-188 and eval

SUBMITTER: Kanellopoulos P 

PROVIDER: S-EPMC11748620 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature